Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Exp Dermatol. 2015 Feb;24(2):155–157. doi: 10.1111/exd.12613

Figure 2.

Figure 2

Scavenging of mitochondrial ROS attenuates the elesclomol-mediated killing of J/EGFPhigh melanoma cells. (a) The decrease of J/EGFPhigh WM3734 cells seen under treatment with elesclomol is reversed in the presence of the mitochondria-targeted antioxidant Mito-Tempo. Box plots were calculated from three independently performed flow cytometric experiments. Asterisk indicates statistical significance with P < 0.05 (ns, non-significant). (b) Crystal violet staining of WM3734 cells (total population) after 24, 48 and 72 h of incubation with elesclomol and mito-Tempo at the indicated concentrations. Shown is one representative example of three independent experiments. Error bars represent the standard deviation.